Skip to content

A Randomized, pilot study, subject-masked comparison of visual function after bilateral implantation of Presbyopia-correcting IOLs

A Randomized, pilot study, subject-masked comparison of visual function after bilateral implantation of Presbyopia-correcting IOLs - M10-070

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34149
Enrollment
15
Registered
2010-12-30
Start date
2011-09-15
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bilateral cataract stare

Interventions

An AcrySof IQ ReSTOR +3.0 D IOL or LENTIS® Mplus IOL, depending on randomization, will be implanted into the posterior capsule of the first operative eye (surgeon*s discretion).

Sponsors

Alcon Laboratories
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subjects are eligible for the study if they meet the following criteria: Note: Ocular criteria must be met in both eyes. * are willing and able to understand and sign an informed consent; * * 1.00 Dioptres of corneal astigmatism in both eyes * are willing and able to attend postoperative examinations per protocol schedule; * are at least 21 years of age, of either gender and any race; * require cataract extraction followed by posterior IOL implantation used as an on-label procedure; * be willing to have second eye surgery within one month of first eye surgery; Note: The second eye surgery should not be performed less than one week (7 days) after the first eye surgery. * are in good ocular health, with the exception of cataracts; * are free of disease(s)/condition(s) listed in the *Caution* section of the AcrySof® ReSTOR® +3 and LENTIS® Mplus package inserts

Exclusion criteria

Exclusion criteria: * Planned multiple procedures, including LRI, during cataract/IOL implantation surgery * Amblyopia * Previous corneal surgery * Clinically significant corneal endothelial dystrophy (e.g., Fuchs* dystrophy) * History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) * Diabetic retinopathy * Macular degeneration * Subjects with pupil abnormalities (e.g., corectopia) * History of retinal detachment * Subjects that have an acute or chronic disease or illness that would increase the operative risk or confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness) * suturing of incision required at time of surgery

Design outcomes

Primary

MeasureTime frame
Primary Outcome parameter is unilateral uncorrected near visual acuity (40cm).

Secondary

MeasureTime frame
Exploratory outcome measurements include - Unilateral uncorrected distance and uncorrected intermediate visual acuity - Bilateral uncorrected distance, near and intermediate vision - Contrast Sensitivity (unilateral and bilateral) Range of functional vision using binocular defocus curve with best distance correction - Reading speed Safety parameters include any adverse events during the course of the study. All adverse events and Alcon product related complaints will be collected at all study visits. The complete study plan is presented in table 18.1

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)